3.4 C
Warsaw
Tuesday, November 17, 2026
spot_imgspot_img

Top 5 This Week

spot_img

Related Posts

Mainstream UK Pharmacy Launches Medical Cannabis Service

spot_imgspot_img
Credit: Getty Images

As a sign of how large and mainstream the medical cannabis industry is becoming in the United Kingdom, major pharmacy chain Boots announced today that it has launched a doctor-led medical cannabis service.

“As the UK’s largest pharmacy chain, and one of the most trusted brands in the country, Boots plays a vital role as a community pharmacy, caring for people, customers and patients everywhere.” Boots describes itself on its website. “Our pharmacies, from community stores to flagship destinations, are committed to supporting our patients and customers for life through a wide range of services.”

The medical cannabis service is called ‘SureLeaf’ and will help “people living with eligible chronic pain conditions, generalised anxiety disorder or insomnia.” SureLeaf will help eligible patients obtain medical cannabis when “conventional treatments have not provided adequate symptom relief.”

Boots also announced that it is exploring a collaborative research effort with the University of Nottingham, focusing on “examining patient outcomes, prescribing practices and experience in the treatment of chronic pain.”

“At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.” said Jamie Kerruish, Chief Healthcare Officer at Boots, in a news release.

“Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care. Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.” Kerruish continued.

“Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis. SureLeaf has therefore been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.” added Dr. David Gwynne, Medical Director at Boots.

Nearly two million medical cannabis products were privately prescribed in the United Kingdom during the last year for which statistics are available, according to data from the NHS Business Services Authority. The NHS Business Services Authority is part of the Department of Health and Social Care and is “responsible for providing platforms and delivering services that support the priorities of the NHS, Government and local health economies.”

Sponsored Content

This informative article is brought to you by NUBO CBD →

Popular Articles